Petey, a 14-year-old Pit Bull with recurrent grade 2 pulmonary carcinoma, underwent Canine Comprehensive Genomic Profiling (CGP) after his second surgery, which revealed TP53 mutations, DNA repair defects, and an exceptionally high tumor mutational burden. These findings guided the selection of gilvetmab as first-line therapy. After five gilvetmab treatments, Petey has remained in complete remission for 12 months and counting, demonstrating that immunotherapy, when guided by the right biomarker insights, can achieve durable responses in canine cancers with aggressive biology.

Not all lymphomas behave the way they appear under the microscope. Kubo, an 8-year-old German Shepherd, presented with mild lymph node enlargement and early chemosensitivity, yet flow cytometry suggested an aggressive T-cell process while histopathology appeared indolent. This diagnostic mismatch raised questions about the true biology of his disease.

VetOmics Canine Comprehensive Genomic Profiling clarified the biology by identifying an NRAS G13V founder mutation and a subclonal FLT3 exon-14 insertion, an aggressive signaling axis more consistent with his clinical behavior. These findings refined diagnosis, aligned risk expectations, and guided mechanism-based treatment planning, shaping his clinical course.

Leonidas, an 8-year-old Leonberger with recurrent squamous cell carcinoma, was treated with imatinib based on Canine CGP findings including KIT and PDGFRA gains. After developing rare bone marrow suppression, imatinib dose reduction restored tolerance and sustained tumor control, demonstrating how genomics-guided therapy and individualized dosing can achieve both safety and durable efficacy.

Lucy, a 13-year-old Golden Retriever with aggressive metastatic melanoma, was treated with palbociclib after Canine CGP revealed CDK4/6 gains, resulting in a strong and sustained response. This case also explores broader implications for immunotherapy and highlights the value of tumor-specific genomic profiling in guiding personalized and effective treatment strategies for our pets.

Can advanced genome profiling redefine canine cancer diagnosis? Through the compelling cases of Daisy, Avery, Kira, and Simon, Dr. Wang demonstrated how Canine CGP delivers precise diagnostic insights that not only determine cancer types/subtypes, but also guide more effective treatments. As genomics and precision medicine paves the way for a new era in veterinary oncology, Canine CGP is helping redefine how we diagnose and care for dogs with cancer, offering new hope for patients and their families.

Bonnibel, a mixed breed girl, has had an unfortunate history with multiple cancer developed from an early age. Could Bonnibel’s repeated cancer diagnoses be due to a hereditary genetic condition, similar to Li-Fraumeni Syndrome in humans? Could this discovery lead to better health management and prevention strategies for pets?

What secrets do the cancer genomes of Beckett and Sherlock, two courageous Bloodhound search and rescue dogs, hold? Despite battling different cancers, a shared genetic clue was found by Canine CGP. Their story reveals new insights into canine cancer predisposition and oncogensis, and examplifies the importance of such understanding on cancer treatment.